Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

SHE/002393 stock hub

SHE/002393 has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

SHE/002393is not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

5.1B

Shenzhen Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

SHE/002393

In the news

Latest news · SHE/002393

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 17.1P50 24.2P75 37.8

Trailing P/E12.3

P25 23.5P50 41.3P75 83.2

ROE8.9

P25 -0.9P50 4.1P75 8.8

ROIC4.7

P25 -0.5P50 5P75 11.4

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All SHE/002393 market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

236

Groups with data

Currency

CNY

Showing 236 of 236 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	China
Country code	CN
Employees	1,605
Employees Change	1%
Employees Change Percent	0.06
Enterprise value	CNY 2.7B
Exchange	Shenzhen Stock Exchange
Financial currency	CNY
First seen	2026-05-10
Industry	Drug Manufacturers - Specialty & Generic
Isin	CNE100000NJ9
Last refreshed	2026-05-10
Market cap	CNY 5.1B
Price	CNY 16.5
Price currency	CNY
Rev Per Employee	843,898.13x
Sector	Healthcare
Sic	2834
Symbol	she/002393
Website	https://www.lishengpharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	8.12%
EV Earnings	6.49x
EV/EBIT	24.61x
EV/EBITDA	14.45x
EV/FCF	12.48x
EV/Sales	1.98x
FCF yield	4.22%
P/B ratio	1.1x
P/E ratio	12.28x
P/S ratio	3.75x
PE Ratio10 Y	58.65x
PE Ratio3 Y	18.11x
PE Ratio5 Y	40.57x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	8.04%
EBITDA Margin	13.38%
FCF margin	15.85%
Gross margin	52.89%
Gross Profit	CNY 716.3M
Gross Profit Growth	-2.4%
Gross Profit Growth Q	-14.33%
Gross Profit Growth3 Y	2.93%
Gross Profit Growth5 Y	1.71%
Net Income	CNY 412.9M
Net Income Growth	128.56%
Net Income Growth Q	-6.14%
Net Income Growth Years	1%
Net Income Growth3 Y	61.43%
Net Income Growth5 Y	108.75%
Pretax Margin	33.26%
Profit Margin	30.48%
Profit Per Employee	CNY 257,253
Profitable Years	20
ROA	1.2
Roa5y	0.84
ROCE	2.27
ROE	8.85
Roe5y	5.11
ROIC	4.66
Roic5y	2.56

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-0.99%
Cagr15y	-1.25%
Cagr1y	22.98%
Cagr3y	8.22%
Cagr5y	10.69%
Div CAGR10	13.57%
Div CAGR3	68.22%
Div CAGR5	70.2%
EPS Growth	130.2
EPS Growth Q	-4.74
EPS Growth Years	1
EPS Growth3 Y	61.89
EPS Growth5 Y	106.2
FCF Growth3 Y	-12.01%
OCF Growth	3,541.44%
OCF Growth10 Y	4.75%
OCF Growth3 Y	-11.18%
OCF Growth5 Y	86.81%
Revenue Growth	0.99x
Revenue Growth Q	-10.16x
Revenue Growth Years	4x
Revenue Growth3 Y	4.83x
Revenue Growth5 Y	3.58x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	CNY 0.24
Assets	CNY 5.5B
Cash	CNY 2.5B
Current Assets	CNY 3.3B
Current Liabilities	CNY 729.3M
Debt	CNY 43.9M
Debt EBITDA	CNY 0.24
Debt Equity	CNY 0.01
Debt FCF	CNY 0.2
Equity	CNY 4.6B
Interest Coverage	48.31
Liabilities	CNY 893.6M
Long Term Assets	CNY 2.2B
Long Term Liabilities	CNY 164.3M
Net Cash	CNY 2.4B
Net Cash By Market Cap	CNY 47.96
Net Cash Growth	17.28%
Net Debt EBITDA	CNY -13.45
Net Debt Equity	CNY -0.53
Net Debt FCF	CNY -11.36
Tangible Book Value	CNY 4.4B
Tangible Book Value Per Share	CNY 14.13
WACC	4.05

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	4.52
Inventory Turnover	2.85
Net Working Capital	CNY 126.7M
Quick ratio	4.17
Working Capital	CNY 2.6B
Working Capital Turnover	CNY 0.55

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	0.7%
Dividend Growth	191.43%
Dividend Growth Years	0%
Dividend per share	CNY 1
Dividend Years	16
Dividend Yield	6.06%
Ex Div Date	2026-04-28
Last Dividend	CNY 0.6
Payout Frequency	Semi-Annual
Payout Ratio	41.91%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-9.47%
1Y total return	22.96%
200-day SMA	18.83
3Y total return	26.77%
50-day SMA	18.68
50-day SMA vs 200-day SMA	50under200
5Y total return	66.17%
All Time High	35.7
All Time High Change	-53.78%
All Time High Date	2015-06-15
All Time Low	9.8
All Time Low Change	68.4%
All Time Low Date	2021-02-04
ATR	0.51
Beta	-0.04
Beta1y	0
Beta2y	0.35
Ch YTD	-8.8
High	16.67
High52	23.98
High52 Date	2025-07-18
High52ch	-31.18%
Low	16.4
Low52	13.81
Low52 Date	2025-05-15
Low52ch	19.64%
Ma50ch	-11.66%
Price vs 200-day SMA	-12.36%
RSI	27.86
RSI Monthly	49.9
RSI Weekly	38.87
Sharpe ratio	0.75x
Sortino ratio	1.45
Total Return	6.76%
Tr YTD	-4.91
Tr15y	-17.2%
Tr1m	-13.49%
Tr1w	-1.32%
Tr3m	-6.8%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	CNY 108.9M
Operating Income Growth	64.09
Operating Income Growth Q	42.94
Operating Income Growth3 Y	18.05
Operating Income Growth5 Y	17.97
Operating margin	8.04

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	145,396,316%
Net Borrowing	-8,555,670
Shares Insiders	1.01%
Shares Institutions	2.37%
Shares Out	308,124,236
Shares Qo Q	1.52%
Shares Yo Y	-0.7%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	CNY 214.7M
Average Volume	5,168,750.25x
Bv Per Share	14.8
CAPEX	CNY -34.8M
Ch10y	-23.91
Ch15y	-35.76
Ch1m	-15.89
Ch1w	-1.32
Ch1y	17.93
Ch3m	-10.61
Ch3y	14.78
Ch5y	47.52
Ch6m	-8.63
Change	-0.54%
Change From Open	-0.48
Close	16.59
Days Gap	-0.06
Depreciation Amortization	72,392,741
Dollar Volume	65,159,985
Earnings Date	2026-04-24
EBIT	CNY 108.9M
EBITDA	CNY 181.3M
EPS	CNY 1.34
F Score	5
FCF	CNY 214.7M
FCF EV Yield	8.01x
FCF Per Share	CNY 0.7
Financing CF	-172,755,486
Fiscal Year End	December
Founded	1,951
Goodwill	70,266,793
Graham Number	21.15449
Graham Upside	28.21
Income Tax	CNY 31.3M
Investing CF	-238,423,613
Is Primary Listing	1
Last Earnings Date	2026-04-24
Last Report Date	2026-03-31
Last Split Date	2026-04-28
Last Split Type	Forward
Lynch Fair Value	CNY 33.6
Lynch Upside	103.6
Ma150	18.38
Ma150ch	-10.2%
Ma20	18.48
Ma20ch	-10.69%
Net CF	-161,718,681
Next Earnings Date	2026-08-21
Open	16.58
P FCF Ratio	23.68
P OCF Ratio	20.38
Payment Date	2026-04-28
Position In Range	37.04
Ppne	954,275,434
Price Date	2026-05-08
Price EBITDA	CNY 28.04
Ptbv Ratio	1.16
Relative Volume	0.74x
Revenue	1,354,456,501x
Tax By Revenue	2.31x
Tax Rate	6.95%
Tr6m	-4.73%
Volume	3,949,090

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

SHE/002393 dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+6.1%

$1.00 annual per share

Payout ratio

+41.9%

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

+70.2%

0 consecutive years of growth

Total shareholder yield

+6.8%

Next ex-dividend date: 2026-04-28

Performance

SHE/002393 stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns SHE/002393?

Insider, institutional, and short-interest positioning.

Institutional ownership

+2.4%

Share of float held by funds and institutions

Insider ownership

+1.0%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

-0.7%

Negative means the company is buying back shares.

Technical

SHE/002393 momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

27.9

Below 30: short-term oversold

Price vs 200-day MA

-12.4%

50/200-day relationship not available

Beta (5Y)

-0.04

Less volatile than the market

Sharpe ratio

0.75

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About SHE/002393

Hub-level FAQ points readers to the deeper analysis pages.

What is the current she/002393 stock rating?

she/002393 is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full she/002393 analysis?

The full report lives at /stocks/she/002393/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for she/002393?

The latest report frames she/002393 around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the she/002393 page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.